新辅助性多种药物系统治疗方法用于肝移植,治疗周周胆管胆管癌
Nadine Soliman1, Ashton A Connor2,3, Ashish Saharia2,3
1Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.
Transplantation direct
|February 12, 2025
概括
新辅助剂格美西塔和西斯系统疗法 (ST) 显示了类似的结果,以辐射为基础的疗法为周围胆管癌 (phCCA) 患者接受肝移植 (LT). 这表明,在LT之前,非辐射选择可能是可行的phCCA治疗.
科学领域:
- 肝胆道手术 肝胆道手术
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 周围胆管癌 (phCCA) 在肝移植 (LT) 后表现出良好的结果.
- 基于新辅助辐射的局部区域疗法是目前phCCA的治疗标准.
- 在LT之前,新辅助体凝胺和青 (gem/cis) 系统治疗 (ST) 的疗效仍未研究.
研究的目的:
- 为了比较 neoadjuvant gem/cis ST 单独与基于辐射的方法的疗效,在接受 LT 的 phCCA 患者中比较.
- 评估结果,包括移植后的整体存活率 (OS),无复发存活率 (RFS),等待名单时间和病理性瘤反应.
主要方法:
- 在2008年1月至2023年2月期间接受LT的27名phCCA患者的回顾性审查.
- 患者根据新辅助疗法进行分类:单独使用gem/cis ST或ST与放射治疗 (RT).
- 分析的结果包括OS,RFS,等候名单持续时间和病理瘤特征.
主要成果:
- 在26名符合条件的患者中,12名接受gem/cis ST,14名接受RT (6名同时接受gem/cis ST).
- 平均等待时间为199天,并且在各组之间没有差异.
- 在gem/cis ST和RT组之间没有观察到OS,RFS或病理瘤反应的显著差异.
结论:
- 新辅助剂gem/cis ST和基于辐射的疗法在phCCA中产生类似的LT后结果.
- 没有接受RT的phCCA患者在特定的机构协议下仍然可能是LT的候选人.
- 这些发现支持在肝移植之前探索phCCA的非辐射新辅助疗法.
相关概念视频
01:28Esophageal Varices-II: Clinical Features and Management
884
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
884
01:22Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
01:29Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
01:26Kidney Transplant II: Surgical Procedure
926
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
926
01:16Kidney Transplant III: Nursing Management
631
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
631